Company Overview and News
KUALA LUMPUR (July 20): Based on corporate announcements and news flow, companies that may be in focus on Monday (July 23) include the following: Gamuda Bhd, Iskandar Waterfront City Bhd, BIMB Holdings Bhd, Salcon Bhd, Cabnet Holdings Bhd, Sunway Construction Group Bhd, Sunway Real Estate Investment Trust and Media Chinese International Ltd. Gamuda Bhd’s 40% associate Syarikat Pengeluar Air Selangor Holdings Sdn Bhd (Splash) has withdrawn its claims against Syarikat Bekalan Air Selangor Sdn Bhd (Syabas) in order to facilitate negotiations on the disposal of Splash with the State government of Selangor.
5090 5258 1589 5176 5263
KUALA LUMPUR(July 20): A unit of Media Chinese International Ltd has entered into agreements to dispose of two companies — Beijing OMG Advertising Company Ltd and Beijing Time Resources Technology Consulting Ltd — that run magazine operations in mainland China.
Media sector Maintain underweight: We expect advertising expenditure (adex) to decline in second half of 2018 (2H18) without adex-friendly events. Apart from the soaring newsprint price, print will remain unfavourable as the sector has not seen any improvement in circulation rate and advertising growth.
4502 5090 6084 MIAHF
KUALA LUMPUR (July 5): The road ahead will be tougher for media players, especially those in print, given the soft advertising market amid an uneventful second half of the year (2H18), according to a local bank-backed research house.
4502 5090 6084 MIAHF
SINAR Harian has become the latest member to join the Malaysia Premium Publishers Marketplace (MPPM), a publisher cooperative that aims to enhance brand safety, establish standards to protect the interest of advertisers, provide better transparency and improve viewability.
5090 5754 6084
Bursa Malaysia resumed afternoon session on a easier note, reversing its earlier gains on the back of weak buying momentum especially for bluechips in Kuala Lumpur June 29, 2017. — Bernama picKUALA LUMPUR, March 28 — Bursa Malaysia remained in the red at mid-morning today, on renewed concerns of a trade war.
5090 PBLOF 1295 BSMAF HIPEF 1818 5199
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...